Color Vision and Microperimetry Changes in Nonexudative Age-Related Macular Degeneration After Risuteganib Treatment : Exploratory Endpoints in a Multicenter Phase 2a Double-Masked, Randomized, Sham-Controlled, Crossover Clinical Trial

BACKGROUND AND OBJECTIVE: To explore the association between best-corrected visual acuity (BCVA) improvement and changes in microperimetry (MP) and color vision in patients with nonexudative age-related macular degeneration following administration of two 1.0-mg intravitreal doses of risuteganib

Bibliographische Detailangaben
Veröffentlicht in:Ophthalmic surgery, lasers & imaging retina. - 2013. - 53(2022), 8 vom: 12. Aug., Seite 430-438
1. Verfasser: Lad, Eleonora M (VerfasserIn)
Weitere Verfasser: Boyer, David S, Heier, Jeffrey S, Kornfield, Julie A, Kuppermann, Baruch D, Quiroz-Mercado, Hugo, Aubel, Janine M, Karageozian, Lisa S, Karageozian, Hampar L, Sarayba, Melvin A, Karageozian, Vicken H, Kaiser, Peter K
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2022
Zugriff auf das übergeordnete Werk:Ophthalmic surgery, lasers & imaging retina
Schlagworte:Clinical Trial, Phase II Journal Article Multicenter Study Randomized Controlled Trial Angiogenesis Inhibitors Peptides risuteganib